Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

ClinicalTrials.gov ID: NCT01893190

Public ClinicalTrials.gov record NCT01893190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage

Study identification

NCT ID: NCT01893190
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Edge Therapeutics Inc; Industry
Enrollment: 73 participants

Conditions and interventions

Conditions

Interventions

Nimodipine Drug
Nimodipine Microparticles Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2013
Primary completion: Dec 31, 2015
Completion: Dec 31, 2015
Last update posted: Feb 4, 2018

2013 – 2016

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Barrow Neurological Institute	Phoenix	Arizona	85013	—
Ronald Reagan UCLA Medical Center	Los Angeles	California	90095-7436	—
Rush University Medical Center	Chicago	Illinois	60612	—
University of Maryland Medical Cnter	Baltimore	Maryland	21201	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Overlook Medical Center	Summit	New Jersey	07901	—
University of New Mexico	Albuquerque	New Mexico	87131	—
Mount Sinai Medical Center	New York	New York	10029	—
Columbia University	New York	New York	10032	—
Lenox Hill Hospital	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27705	—
Mayfield Clinic Inc	Cincinnati	Ohio	45219	—
The Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Oregon Health and Science University	Portland	Oregon	97239	—
Medical University of South Carolina (MUSC)	Charleston	South Carolina	29425	—
Vanderbilt University	Nashville	Tennessee	37232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01893190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 4, 2018 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01893190 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →